Safety and Effects of Ramipril Combined With Candesartan

This study has been completed.
Sponsor:
Information provided by:
Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:
NCT00356395
First received: July 25, 2006
Last updated: NA
Last verified: March 2006
History: No changes posted
  Purpose

we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.


Condition Intervention Phase
Hypertension
Drug: ramipril, candesartan
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients

Resource links provided by NLM:


Further study details as provided by Gachon University Gil Medical Center:

Primary Outcome Measures:
  • comparison of endothelium-dependent dilation among the 3 treatment schemes

Estimated Enrollment: 40
Study Start Date: August 2003
Estimated Study Completion Date: March 2006
Detailed Description:

Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).

  Eligibility

Ages Eligible for Study:   35 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with mild to moderate hypertension

Exclusion Criteria:

  • We will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00356395

Sponsors and Collaborators
Gachon University Gil Medical Center
Investigators
Principal Investigator: Kwang K Koh, MD Cardiology, Gil Heart Center, Gachon Medical School
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00356395     History of Changes
Other Study ID Numbers: 2003-008
Study First Received: July 25, 2006
Last Updated: July 25, 2006
Health Authority: Korea: Food and Drug Administration

Keywords provided by Gachon University Gil Medical Center:
endothelial function, insulin resistance, adipocytokines

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Ramipril
Candesartan
Candesartan cilexetil
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists

ClinicalTrials.gov processed this record on August 21, 2014